AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Fluorescent CDK Inhibitors for the Treatment and Diagnosis of Cancer

Technology Benefits

Compounds of the invention demonstrate higher % inhibition of CDK2/A and CDK2/E than known CDK2 inhibitor, seliciclibAfluorescent label allow these compounds to be used as both atherapeutic to treat cancer and a diagnostic to detect cancerous cellsand monitor treatmentCell growth inhibition potency (IC50) in certain cancer cell lines is superior to known CDK inhibitors purvanalol and seliciclib

Detailed Technology Description

The invention describes promising new fluorescent small moleculepharmaceutical leads for the treatment of cancer by inhibition ofcyclin dependant kinase (CDK). The novel compounds are more potent thanknown CDK inhibitors, purvalanols A and B as well as phase II clinicaldrug candidate, roscovitine (seliciclib). These compounds areespecially potent inhibitors of CDK2 isoforms and effectively arresttumor cells in the G2/M phase. These new compounds may be an effectivenew tool for not only for treating, but also diagnosing cancer andmonitoring cancer therapy.

Country/Region

USA

For more information, please click Here